Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 15/20 | 0.68 |
| ▸ | PNP | P00491 | 2/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21127947 | 1.00 | HPRT1 (0.68) | HPRT1PNPADORA2A | |
| SCHEMBL20782416 | 0.88 | HPRT1 (0.65) | HPRT1PNPADORA2A | |
| SCHEMBL7812374 | 0.84 | HPRT1 (0.70) | HPRT1PNP | |
| SCHEMBL6673871 | 0.83 | ADORA2B (0.57) | HPRT1PNPADORA2A | |
| SCHEMBL1993930 | 0.82 | HPRT1 (0.63) | HPRT1PNPADORA2A | |
| SCHEMBL6673671 | 0.81 | ADORA2B (0.55) | HPRT1PNPADORA2A | |
| SCHEMBL6060863 | 0.81 | HPRT1 (0.65) | HPRT1PNP | |
| SCHEMBL22571178 | 0.80 | TK1 (0.74) | HPRT1PNP | |
| SCHEMBL6272299 | 0.80 | TK1 (0.74) | HPRT1PNP | |
| SCHEMBL489056 | 0.80 | TK1 (0.74) | HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-20200157518-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | HPRT1 635/4885PNP 220/4885ADORA2A 660/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | HPRT1 566/4885PNP 223/4885ADORA2A 652/4885 |
| US-20200157518-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CD2, PBK, CD4 | HPRT1 514/4885PNP 288/4885ADORA2A 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.